Gilead Sciences (GILD) Competitors

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Is GILD or AMGN a better dividend stock?

Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 3.0%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.0%. Gilead Sciences pays out 854.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 126.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Which has more volatility & risk, GILD or AMGN?

Gilead Sciences has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Which has higher earnings and valuation, GILD or AMGN?

Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$28.75B	4.62	$480M	$0.37	288.49
Amgen	$33.42B	5.05	$4.09B	$7.55	41.64

Do insiders & institutionals have more ownership in GILD or AMGN?

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by insiders. Comparatively, 0.7% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Is GILD or AMGN more profitable?

Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	1.67%	31.63%	10.38%
Amgen	12.24%	176.32%	11.71%

Does the media favor GILD or AMGN?

In the previous week, Amgen had 5 more articles in the media than Gilead Sciences. MarketBeat recorded 53 mentions for Amgen and 48 mentions for Gilead Sciences. Amgen's average media sentiment score of 1.53 beat Gilead Sciences' score of 1.16 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	37 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Amgen	52 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts recommend GILD or AMGN?

Gilead Sciences presently has a consensus price target of $104.52, indicating a potential downside of 2.08%. Amgen has a consensus price target of $314.04, indicating a potential downside of 0.11%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than Gilead Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	11 Hold rating(s)	15 Buy rating(s)	3 Strong Buy rating(s)	2.72
Amgen	2 Sell rating(s)	10 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.46

Does the MarketBeat Community favor GILD or AMGN?

Gilead Sciences received 930 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.86% of users gave Gilead Sciences an outperform vote while only 71.87% of users gave Amgen an outperform vote.

Company	Underperform	Outperform
Gilead Sciences	Outperform Votes 2481 76.86%	Underperform Votes 747 23.14%
Amgen	Outperform Votes 1551 71.87%	Underperform Votes 607 28.13%

Summary

Amgen beats Gilead Sciences on 15 of the 22 factors compared between the two stocks.